Clinical Trials
3 trialsNCT07624513 2026-06-03
Determination 2 - Isatuximab, Iberdomide, Bortezomib and Dexamethasone Induction, Followed by Risk- and Response-Adapted Consolidation and Maintenance Therapy, in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma
Dana-Farber Cancer Institute
Phase 3 Not yet recruiting
NCT07601100 2026-06-01
IsaIberVD
Dana-Farber Cancer Institute
Phase 1/2 Not yet recruiting
NCT07437963 2026-04-15
Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse
National Cancer Institute (NCI)
Phase 1/2 Not yet recruiting